Amgen safety net foundation
Amgen safety net foundation refills.
Amgen safety net foundation
Amgen Support Services for Patients with Non-Small Cell Lung Cancer
Helping to Ensure More Patients Have Access to Biomarker Testing
Amgen's Biomarker Assist™ is a program to help more patients with advanced NSCLC gain access to biomarker testing, which is critical in managing the disease.
Through the program, eligible patients may save on biomarker testing.
Biomarker Assist™ is comprised of two programs:
The Next Generation Sequencing (NGS) Affordability Program helps eligible patients (commercially or privately insured) with out-of-pocket costs for a comprehensive biomarker panel.
This panel is for patients who have advanced or metastatic (stage IV) NSCLC, and it must include the KRAS gene.
The KRAS Single Gene Test (SGT) Program provides a KRAS Mutation Analysis at no cost to any eligible patient, regardless of a patient’s results and insurance.
Patients will receive results from participating NeoGenomics Laboratorie